| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| September 27th, 2005 | 22 | Yes |
Popular Name: N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine N-(3-Bromophenyl)-6,7-dimethoxyq…
Find On: PubMed — Wikipedia — Google
CAS Numbers: 153436-54-5 , 183322-45-4 , [153436-54-5] , [183322-45-4]
4-(3-Bromoanilino)-6,7-dimethoxyquinazoline
4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-
4-Quinazolinamine,N- -6,7-dimethoxy-,monohydrochloride
4-Quinazolinamine,N-(3-bromophenyl)-6,7-dimethoxy-
4-[(3-Bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride
N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride
N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-aminehydrochloride
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 4.06 | 8.59 | -10.58 | 1 | 5 | 0 | 56 | 360.211 | 4 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| Purity | 95% | Fluorochem |
| Target | EGFR | Selleck Chemicals |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| ABL1-1-E | Tyrosine-protein Kinase ABL (cluster #1 Of 1), Eukaryotic | Eukaryotes | 30 | 0.48 | Binding ≤ 10μM |
| EGFR-3-E | Epidermal Growth Factor Receptor ErbB1 (cluster #3 Of 4), Eukaryotic | Eukaryotes | 70 | 0.46 | Binding ≤ 10μM |
| EPHB2-1-E | Ephrin Type-B Receptor 2 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8100 | 0.32 | Binding ≤ 10μM |
| ERBB2-2-E | Receptor Protein-tyrosine Kinase ErbB-2 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 70 | 0.46 | Binding ≤ 10μM |
| F16P1-1-E | Fructose-1,6-bisphosphatase 1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 1000 | 0.38 | Binding ≤ 10μM |
| LCK-1-E | Tyrosine-protein Kinase LCK (cluster #1 Of 4), Eukaryotic | Eukaryotes | 8100 | 0.32 | Binding ≤ 10μM |
| MK11-1-E | MAP Kinase P38 Beta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 6300 | 0.33 | Binding ≤ 10μM |
| MK12-2-E | MAP Kinase P38 Gamma (cluster #2 Of 2), Eukaryotic | Eukaryotes | 6300 | 0.33 | Binding ≤ 10μM |
| MK13-1-E | MAP Kinase P38 Delta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 6300 | 0.33 | Binding ≤ 10μM |
| MK14-3-E | MAP Kinase P38 Alpha (cluster #3 Of 3), Eukaryotic | Eukaryotes | 6300 | 0.33 | Binding ≤ 10μM |
| MKNK1-1-E | MAP Kinase-interacting Serine/threonine-protein Kinase MNK1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 630 | 0.39 | Binding ≤ 10μM |
| SRC-1-E | Tyrosine-protein Kinase SRC (cluster #1 Of 3), Eukaryotic | Eukaryotes | 1400 | 0.37 | Binding ≤ 10μM |
| VGFR2-2-E | Vascular Endothelial Growth Factor Receptor 2 (cluster #2 Of 2), Eukaryotic | Eukaryotes | 1489 | 0.37 | Binding ≤ 10μM |
| EGFR-1-E | Epidermal Growth Factor Receptor ErbB1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4 | 0.53 | Functional ≤ 10μM |
| ERBB2-2-E | Receptor Protein-tyrosine Kinase ErbB-2 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 143 | 0.44 | Functional ≤ 10μM |
| ERBB4-1-E | Receptor Protein-tyrosine Kinase ErbB-4 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 49 | 0.47 | Functional ≤ 10μM |
| Z100492-1-O | MCF10 (Normal Breast Epithelial Cells) (cluster #1 Of 1), Other | Other | 211 | 0.42 | Functional ≤ 10μM |
| Z100731-1-O | Bcap37 (Breast Carcinoma Cells) (cluster #1 Of 1), Other | Other | 8900 | 0.32 | Functional ≤ 10μM |
| Z103205-3-O | A431 (cluster #3 Of 4), Other | Other | 4400 | 0.34 | Functional ≤ 10μM |
| Z80037-1-O | Balb/MK (cluster #1 Of 1), Other | Other | 200 | 0.43 | Functional ≤ 10μM |
| Z80224-1-O | MCF7 (Breast Carcinoma Cells) (cluster #1 Of 14), Other | Other | 4700 | 0.34 | Functional ≤ 10μM |
| Z80390-1-O | PC-3 (Prostate Carcinoma Cells) (cluster #1 Of 10), Other | Other | 8900 | 0.32 | Functional ≤ 10μM |
| Z80475-3-O | SK-BR-3 (Breast Adenocarcinoma) (cluster #3 Of 3), Other | Other | 820 | 0.39 | Functional ≤ 10μM |
| Z80852-3-O | A-431 (Epidermoid Carcinoma Cells) (cluster #3 Of 3), Other | Other | 8310 | 0.32 | Functional ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 0.66 | 0.58 | Binding ≤ 1μM |
| F16P1_HUMAN | P09467 | Fructose-1,6-bisphosphatase, Human | 1000 | 0.38 | Binding ≤ 1μM |
| MKNK1_HUMAN | Q9BUB5 | MAP Kinase-interacting Serine/threonine-protein Kinase MNK1, Human | 630 | 0.39 | Binding ≤ 1μM |
| ERBB2_HUMAN | P04626 | Receptor Protein-tyrosine Kinase ErbB-2, Human | 70 | 0.46 | Binding ≤ 1μM |
| ABL1_HUMAN | P00519 | Tyrosine-protein Kinase ABL, Human | 30 | 0.48 | Binding ≤ 1μM |
| EPHB2_HUMAN | P29323 | Ephrin Type-B Receptor 2, Human | 8100 | 0.32 | Binding ≤ 10μM |
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 0.66 | 0.58 | Binding ≤ 10μM |
| F16P1_HUMAN | P09467 | Fructose-1,6-bisphosphatase, Human | 1000 | 0.38 | Binding ≤ 10μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 6300 | 0.33 | Binding ≤ 10μM |
| MK11_HUMAN | Q15759 | MAP Kinase P38 Beta, Human | 6300 | 0.33 | Binding ≤ 10μM |
| MK13_HUMAN | O15264 | MAP Kinase P38 Delta, Human | 6300 | 0.33 | Binding ≤ 10μM |
| MK12_HUMAN | P53778 | MAP Kinase P38 Gamma, Human | 6300 | 0.33 | Binding ≤ 10μM |
| MKNK1_HUMAN | Q9BUB5 | MAP Kinase-interacting Serine/threonine-protein Kinase MNK1, Human | 630 | 0.39 | Binding ≤ 10μM |
| ERBB2_HUMAN | P04626 | Receptor Protein-tyrosine Kinase ErbB-2, Human | 70 | 0.46 | Binding ≤ 10μM |
| ABL1_HUMAN | P00519 | Tyrosine-protein Kinase ABL, Human | 30 | 0.48 | Binding ≤ 10μM |
| LCK_HUMAN | P06239 | Tyrosine-protein Kinase LCK, Human | 8100 | 0.32 | Binding ≤ 10μM |
| SRC_HUMAN | P12931 | Tyrosine-protein Kinase SRC, Human | 1400 | 0.37 | Binding ≤ 10μM |
| VGFR2_HUMAN | P35968 | Vascular Endothelial Growth Factor Receptor 2, Human | 1489 | 0.37 | Binding ≤ 10μM |
| Z80852 | Z80852 | A-431 (Epidermoid Carcinoma Cells) | 1520 | 0.37 | Functional ≤ 10μM |
| Z103205 | Z103205 | A431 | 4400 | 0.34 | Functional ≤ 10μM |
| Z80037 | Z80037 | Balb/MK | 200 | 0.43 | Functional ≤ 10μM |
| Z100731 | Z100731 | Bcap37 (Breast Carcinoma Cells) | 8900 | 0.32 | Functional ≤ 10μM |
| EGFR_HUMAN | P00533 | Epidermal Growth Factor Receptor ErbB1, Human | 2.6 | 0.55 | Functional ≤ 10μM |
| Z100492 | Z100492 | MCF10 (Normal Breast Epithelial Cells) | 211 | 0.42 | Functional ≤ 10μM |
| Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 1613 | 0.37 | Functional ≤ 10μM |
| Z80390 | Z80390 | PC-3 (Prostate Carcinoma Cells) | 8900 | 0.32 | Functional ≤ 10μM |
| ERBB2_HUMAN | P04626 | Receptor Protein-tyrosine Kinase ErbB-2, Human | 143 | 0.44 | Functional ≤ 10μM |
| ERBB4_HUMAN | Q15303 | Receptor Protein-tyrosine Kinase ErbB-4, Human | 49 | 0.47 | Functional ≤ 10μM |
| Z80475 | Z80475 | SK-BR-3 (Breast Adenocarcinoma) | 820 | 0.39 | Functional ≤ 10μM |
| Description | Species |
|---|---|
| activated TAK1 mediates p38 MAPK activation | |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
| Activation of the AP-1 family of transcription factors | |
| ADP signalling through P2Y purinoceptor 1 | |
| CD28 co-stimulation | |
| CD28 dependent PI3K/Akt signaling | |
| CD28 dependent Vav1 pathway | |
| CDO in myogenesis | |
| Constitutive PI3K/AKT Signaling in Cancer | |
| CTLA4 inhibitory signaling | |
| DAP12 signaling | |
| Downregulation of ERBB2:ERBB3 signaling | |
| Downstream TCR signaling | |
| DSCAM interactions | |
| EGFR downregulation | |
| EGFR interacts with phospholipase C-gamma | |
| EGFR Transactivation by Gastrin | |
| EPH-ephrin mediated repulsion of cells | |
| EPH-Ephrin signaling | |
| EPHA-mediated growth cone collapse | |
| EPHB-mediated forward signaling | |
| Ephrin signaling | |
| ERK/MAPK targets | |
| Factors involved in megakaryocyte development and platelet production | |
| GAB1 signalosome | |
| Generation of second messenger molecules | |
| Gluconeogenesis | |
| GPVI-mediated activation cascade | |
| GRB2 events in EGFR signaling | |
| GRB2 events in ERBB2 signaling | |
| GRB7 events in ERBB2 signaling | |
| Integrin cell surface interactions | |
| Interleukin-2 signaling | |
| KSRP destabilizes mRNA | |
| L1CAM interactions | |
| Nef and signal transduction | |
| Nef Mediated CD4 Down-regulation | |
| Neurophilin interactions with VEGF and VEGFR | |
| NOD1/2 Signaling Pathway | |
| Oxidative Stress Induced Senescence | |
| p38MAPK events | |
| PD-1 signaling | |
| PECAM1 interactions | |
| Phosphorylation of CD3 and TCR zeta chains | |
| PI3K events in ERBB2 signaling | |
| PIP3 activates AKT signaling | |
| Platelet sensitization by LDL | |
| PLCG1 events in ERBB2 signaling | |
| Regulation of actin dynamics for phagocytic cup formation | |
| Regulation of KIT signaling | |
| Role of Abl in Robo-Slit signaling | |
| Sema4D induced cell migration and growth-cone collapse | |
| SHC1 events in EGFR signaling | |
| SHC1 events in ERBB2 signaling | |
| Signal transduction by L1 | |
| Signaling by constitutively active EGFR | |
| Signaling by EGFR | |
| Signaling by ERBB2 | |
| Signaling by ERBB4 | |
| Signaling by SCF-KIT | |
| Spry regulation of FGF signaling | |
| Translocation of ZAP-70 to Immunological synapse | |
| VEGF binds to VEGFR leading to receptor dimerization | |
| VEGFA-VEGFR2 Pathway | |
| VEGFR2 mediated cell proliferation |
No pre-computed analogs available. Try a structural similarity search.